Cortex Reports Positive Effects of CX717 in Human Sleep Deprivation Study

Cortex Pharmaceuticals announced that preliminary analysis suggests that CX717, when compared to placebo, increased wakefulness in a dose-related manner and improved performance in healthy male subjects that became impaired during 27 hours without sleep.

The study was performed in the UK at the Academic Clinic for Disorders of Sleep and Wakefulness at University of Surrey.

In the study, 16 young healthy men were administered three different doses of CX717 and a placebo control in a randomized, double-blind, four-way crossover design. All subjects were sleep deprived for 27 hours during which time they were tested on measures of memory, attention, vigilance, reaction time and executive function.

Propensity to fall sleep was measured with a modified wakefulness test given at 4 a.m. on the night of testing. The integrity of recovery sleep was assessed by polysomnography.